维普中文期刊产品整合服务

Intranasal Immunization Using CTA1-DD as a Mucosal Adjuvant for an Inactivated Influenza Vaccine

查看全文 作　　者：FAN Xue [1]Ting;WANG Yun [2]Long;SU Qiu [1]Dong;QIU [1]Feng;YI [1]Yao;JIA Zhi [1]Yuan;WANG Da [1]Yan;QIN [1]Kun;ZOU Ye [3]Ning;BI Sheng [1]Li;SHEN Li [1]Ping 高影响力作者 机构地区：[1]National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China;[2]Henan Bioengineering Research Center, Zhengzhou 4500466, Henan, China;[3]Sinovac Biotech Co., Ltd., Beijing 100085, China高影响力机构 出　　处：《Biomedical and Environmental Sciences》索引2019年第32卷第7期,共10页高影响力期刊 基　　金：supported by the Chinese National Science and Technology Major Project for Important Infectious Diseases Control and Prevention [Grant No.2017ZX10105015001002] 摘　　要：Objective To evaluate the effect of intranasal immunization with CTA1-DD as mucosal adjuvant combined with H3N2 split vaccine. Methods Mice were immunized intranasally with PBS(negative control), or H3N2 split vaccine(3 μg/mouse) alone, or CTA1-DD(5 μg/mouse) alone, or H3N2 split vaccine(3 μg/mouse) plus CTA1-DD(5 μg/mouse). Positive control mice were immunized intramuscularly with H3N2 split vaccine(3 μg/mouse) and alum adjuvant. All the mice were immunized twice, two weeks apart. Then sera and mucosal lavages were collected. The specific HI titers, IgM, IgG, IgA, and IgG subtypes were examined by ELISA. IFN-γ and IL-4 were test by ELISpot. In addition, two weeks after the last immunization, surivival after H3N2 virus lethal challenge was measured. Results H3N2 split vaccine formulated with CTA1-DD could elicit higher Ig M, Ig G and hemagglutination inhibition titers in sera. Furthermore, using CTA1-DD as adjuvant significantly improved mucosal secretory Ig A titers in bronchoalveolar lavages and vaginal lavages. Meanwhile this mucosal adjuvant could enhance Th-1-type responses and induce protective hemagglutination inhibition titers. Notably, the addition of CTA1-DD to split vaccine provided 100% protection against lethal infection by the H3N2 virus. Conclusion CTA1-DD could promote mucosal, humoral and cell-mediated immune responses, which supports the further development of CTA1-DD as a mucosal adjuvant for mucosal vaccines. 关 键 词：ADJUVANTS H3N2 INFLUENZA MUCOSAL IMMUNIZATION Split VACCINE
相关文献

参考文献(47)

引证文献(1)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费